The cAMP responsive element binding protein 1 transactivates epithelial membrane protein 2, a potential tumor suppressor in the urinary bladder urothelial carcinoma

Oncotarget

Volumn 6, Issue 11, 2015, Pages 9220-9239

  Li, Chien Feng ^a,b,c   Wu, Wen Jeng ^d,e,f,g   Wu, Wen Ren ^h   Liao, Yu Jing ⁱ   Chen, Lih Ren ^c,i   Huang, Chun Nung ^f,g,h   Li, Ching Chia ^f,g,j   Li, Wei Ming ^d,e,g,k   Huang, Hsuan Ying ^l   Chen, Yi Ling ^h   Liang, Shih Shin ^h,m   Chow, Nan Haw ^n,o   Shiue, Yow Ling ^h  

^a CHI MEI MEDICAL CENTER   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c SOUTHERN TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^d KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^e KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^f KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^g KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^h NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

ⁱ Taiwan Livestock Research Institute   (Taiwan)

^j KAOHSIUNG MUNICIPAL TA TUNG HOSPITAL   (Taiwan)

^k Department of Urology   (Taiwan)

^l CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^m KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

ⁿ NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^o NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

more..

Author keywords

CREB1; EMP2; Tumor suppressor; Urinary bladder urothelial carcinoma

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 2; EPITHELIAL MEMBRANE PROTEIN 2; GENISTEIN; MEMBRANE PROTEIN; UNCLASSIFIED DRUG; CREB1 PROTEIN, HUMAN; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; EMP2 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER CARCINOGENESIS; BLADDER CARCINOMA; CANCER CELL LINE; CANCER GRADING; CANCER INHIBITION; CANCER PROGNOSIS; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; CREB1 GENE; DISEASE FREE SURVIVAL; DISEASE SPECIFIC SURVIVAL; DOWN REGULATION; EMP2 GENE; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE IDENTIFICATION; GENETIC TRANSCRIPTION; HEALTH STATUS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; METASTASIS FREE SURVIVAL; MITOSIS; MOUSE; MULTIVARIATE ANALYSIS; MUTAGENESIS; NONHUMAN; OUTCOME ASSESSMENT; PROMOTER REGION; RNA TRANSLATION; TRANSACTIVATION; TUMOR INVASION; TUMOR SUPPRESSOR GENE; UNIVARIATE ANALYSIS; UPREGULATION; URINARY BLADDER UROTHELIAL CARCINOMA; ANIMAL; BIOSYNTHESIS; BLADDER; BLADDER TUMOR; CANCER TRANSPLANTATION; CELL MOTION; CELL SURVIVAL; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; MORTALITY; NONOBESE DIABETIC MOUSE; PATHOLOGY; RNA INTERFERENCE; SCID MOUSE; TRANSCRIPTION INITIATION; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; FEMALE; G2 PHASE CELL CYCLE CHECKPOINTS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; GENISTEIN; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED NOD; MICE, SCID; MIDDLE AGED; NEOPLASM TRANSPLANTATION; PROMOTER REGIONS, GENETIC; PROTEIN KINASE INHIBITORS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TRANSCRIPTIONAL ACTIVATION; TRANSPLANTATION, HETEROLOGOUS; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 84928714256     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3312     Document Type: Article

References (54)

1. Eble JN, Sauter G, Epstein JI, Sesterhenn IA. (2004). World Health Organization Classification fo Tumour. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon: Interantional Agency for Research on Cancer (IARC) press 2004; pp. 93-109.
2. Reulen RC, Kellen E, Buntinx F, Brinkman M, Zeegers MP. A meta-analysis on the association between bladder cancer and occupation. Scandinavian journal of urology and nephrology Supplementum. 2008; 64-78.
3. Aben KK, Witjes JA, Schoenberg MP, Hulsbergen-van de Kaa C, Verbeek AL, Kiemeney LA. Familial aggregation of urothelial cell carcinoma. International journal of cancer Journal international du cancer. 2002; 98:274-278.
4. Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. The New England journal of medicine. 2000; 343:78-85.
5. Hall RR, Parmar MK, Richards AB, Smith PH. Proposal for changes in cystoscopic follow up of patients with bladder cancer and adjuvant intravesical chemotherapy. BMJ (Clinical research ed). 1994; 308:257-260.
6. Shipley WU, Kaufman DS, Tester WJ, Pilepich MV, Sandler HM. Overview of bladder cancer trials in the Radiation Therapy Oncology Group. Cancer. 2003; 97:2115-2119.
7. Urbanowicz RJ, Andrew AS, Karagas MR, Moore JH. Role of genetic heterogeneity and epistasis in bladder cancer susceptibility and outcome: a learning classifier system approach. Journal of the American Medical Informatics Association : JAMIA. 2013; 20:603-612.
8. Mitra AP, Hansel DE, Cote RJ. Prognostic value of cellcycle regulation biomarkers in bladder cancer. Semin Oncol. 2012; 39:524-533.
9. Volanis D, Papadopoulos G, Doumas K, Gkialas I, Delakas D. Molecular mechanisms in urinary bladder carcinogenesis. Journal of BUON : official journal of the Balkan Union of Oncology. 2011; 16:589-601.
10. Tang L, Zhang Y. Mitochondria are the primary target in isothiocyanate-induced apoptosis in human bladder cancer cells. Molecular cancer therapeutics. 2005; 4:1250-1259.
11. Dixon RA, Ferreira D. Genistein. Phytochemistry. 2002; 60:205-211.
12. Wang YW, Li WM, Wu WJ, Chai CY, Chang TY, Sun Y, Cheng CJ, Shiue YL, Su SJ, Cheng HL, Liu HS, Chow NH. Epithelial membrane protein 2 is a prognostic indictor for patients with urothelial carcinoma of the upper urinary tract. The American journal of pathology. 2013; 183:709-719.
13. Roupret M, Zigeuner R, Palou J, Boehle A, Kaasinen E, Sylvester R, Babjuk M, Oosterlinck W. European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: update. European urology. 2011; 59:584-594.
14. Wu XR. Urothelial tumorigenesis: a tale of divergent pathways. Nat Rev Cancer. 2005; 5:713-725.
15. Wu XR. Biology of urothelial tumorigenesis: insights from genetically engineered mice. Cancer Metastasis Rev. 2009; 28:281-290.
16. Lughezzani G, Burger M, Margulis V, Matin SF, Novara G, Roupret M, Shariat SF, Wood CG, Zigeuner R. Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. European urology. 2012; 62:100-114.
17. Ben-Porath I, Kozak CA, Benvenisty N. Chromosomal mapping of Tmp (Emp1), Xmp (Emp2), and Ymp (Emp3), genes encoding membrane proteins related to Pmp22. Genomics. 1998; 49:443-447.
18. Liehr T, Kuhlenbaumer G, Wulf P, Taylor V, Suter U, Van Broeckhoven C, Lupski JR, Claussen U, Rautenstrauss B. Regional localization of the human epithelial membrane protein genes 1, 2, and 3 (EMP1, EMP2, EMP3) to 12p12.3, 16p13.2, and 19q13.3. Genomics. 1999; 58:106-108.
19. Taylor V, Suter U. Epithelial membrane protein-2 and epithelial membrane protein-3: two novel members of the peripheral myelin protein 22 gene family. Gene. 1996; 175:115-120.
20. Berditchevski F, Odintsova E. Characterization of integrintetraspanin adhesion complexes: role of tetraspanins in integrin signaling. J Cell Biol. 1999; 146:477-492.
21. Jetten AM, Suter U. The peripheral myelin protein 22 and epithelial membrane protein family. Prog Nucleic Acid Res Mol Biol. 2000; 64:97-129.
22. Wadehra M, Sulur GG, Braun J, Gordon LK, Goodglick L. Epithelial membrane protein-2 is expressed in discrete anatomical regions of the eye. Exp Mol Pathol. 2003; 74:106-112.
23. Arinaminpathy Y, Khurana E, Engelman DM, Gerstein MB. Computational analysis of membrane proteins: the largest class of drug targets. Drug discovery today. 2009; 14:1130-1135.
24. Chen YL, Uen YH, Li CF, Horng KC, Chen LR, Wu WR, Tseng HY, Huang HY, Wu LC, Shiue YL. The E2F transcription factor 1 transactives stathmin 1 in hepatocellular carcinoma. Annals of surgical oncology. 2013; 20:4041-4054.
25. Wang CX, Wadehra M, Fisk BC, Goodglick L, Braun J. Epithelial membrane protein 2, a 4-transmembrane protein that suppresses B-cell lymphoma tumorigenicity. Blood. 2001; 97:3890-3895.
26. Wadehra M, Natarajan S, Seligson DB, Williams CJ, Hummer AJ, Hedvat C, Braun J, Soslow RA. Expression of epithelial membrane protein-2 is associated with endometrial adenocarcinoma of unfavorable outcome. Cancer. 2006; 107:90-98.
27. Fu M, Rao R, Sudhakar D, Hogue CP, Rutta Z, Morales S, Gordon LK, Braun J, Goodglick L, Wadehra M. Epithelial membrane protein-2 promotes endometrial tumor formation through activation of FAK and Src. PloS one. 2011; 6:e19945.
28. Mayr B, Montminy M. Transcriptional regulation by the phosphorylation-dependent factor CREB. Nature reviews Molecular cell biology. 2001; 2:599-609.
29. Johannessen M, Delghandi MP, Moens U. What turns CREB on? Cellular signalling. 2004; 16:1211-1227.
30. Mayr BM, Canettieri G, Montminy MR. Distinct effects of cAMP and mitogenic signals on CREB-binding protein recruitment impart specificity to target gene activation via CREB. Proceedings of the National Academy of Sciences of the United States of America. 2001; 98:10936-10941.
31. Ahn S, Olive M, Aggarwal S, Krylov D, Ginty DD, Vinson C. A dominant-negative inhibitor of CREB reveals that it is a general mediator of stimulus-dependent transcription of c-fos. Molecular and cellular biology. 1998; 18:967-977.
32. Desdouets C, Matesic G, Molina CA, Foulkes NS, Sassone-Corsi P, Brechot C, Sobczak-Thepot J. Cell cycle regulation of cyclin A gene expression by the cyclic AMP-responsive transcription factors CREB and CREM. Molecular and cellular biology. 1995; 15:3301-3309.
33. White PC, Shore AM, Clement M, McLaren J, Soeiro I, Lam EW, Brennan P. Regulation of cyclin D2 and the cyclin D2 promoter by protein kinase A and CREB in lymphocytes. Oncogene. 2006; 25:2170-2180.
34. Zhang X, Odom DT, Koo SH, Conkright MD, Canettieri G, Best J, Chen H, Jenner R, Herbolsheimer E, Jacobsen E, Kadam S, Ecker JR, Emerson B, Hogenesch JB, Unterman T, Young RA, et al. Genome-wide analysis of cAMP-response element binding protein occupancy, phosphorylation, and target gene activation in human tissues. Proceedings of the National Academy of Sciences of the United States of America. 2005; 102:4459-4464.
35. Okoshi R, Ando K, Suenaga Y, Sang M, Kubo N, Kizaki H, Nakagawara A, Ozaki T. Transcriptional regulation of tumor suppressor p53 by cAMP-responsive element-binding protein/AMP-activated protein kinase complex in response to glucose deprivation. Genes to cells : devoted to molecular & cellular mechanisms. 2009; 14:1429-1440.
36. Xu XS, Wang L, Abrams J, Wang G. Histone deacetylases (HDACs) in XPC gene silencing and bladder cancer. Journal of hematology & oncology. 2011; 4:17.
37. Seo HS, Choi HS, Choi HS, Choi YK, Um JY, Choi I, Shin YC, Ko SG. Phytoestrogens induce apoptosis via extrinsic pathway, inhibiting nuclear factor-kappaB signaling in HER2-overexpressing breast cancer cells. Anticancer research. 2011; 31:3301-3313.
38. Malumbres M, Barbacid M. Cell cycle kinases in cancer. Current opinion in genetics & development. 2007; 17:60-65.
39. Gautier J, Norbury C, Lohka M, Nurse P, Maller J. Purified maturation-promoting factor contains the product of a Xenopus homolog of the fission yeast cell cycle control gene cdc2+. Cell. 1988; 54:433-439.
40. Takizawa CG, Morgan DO. Control of mitosis by changes in the subcellular location of cyclin-B1-Cdk1 and Cdc25C. Curr Opin Cell Biol. 2000; 12:658-665.
41. Parker LL H. Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase. Science. 1992; 257:1955-1957.
42. Kornbluth S, Sebastian B, Hunter T, Newport J. Membrane localization of the kinase which phosphorylates p34cdc2 on threonine 14. Molecular biology of the cell. 1994; 5:273-282.
43. Mueller PR, Coleman TR, Kumagai A, Dunphy WG. Myt1: a membrane-associated inhibitory kinase that phosphorylates Cdc2 on both threonine-14 and tyrosine-15. Science. 1995; 270:86-90.
44. Liu F, Stanton JJ, Wu Z, Piwnica-Worms H. The human Myt1 kinase preferentially phosphorylates Cdc2 on threonine 14 and localizes to the endoplasmic reticulum and Golgi complex. Molecular and cellular biology. 1997; 17:571-583.
45. Wolfe BA, Gould KL. Inactivating Cdc25, mitotic style. Cell cycle (Georgetown, Tex). 2004; 3:601-603.
46. Donzelli M, Draetta GF. Regulating mammalian checkpoints through Cdc25 inactivation. EMBO reports. 2003; 4:671-677.
47. Peng CY, Graves PR, Ogg S, Thoma RS, Byrnes MJ, 3rd , Wu Z, Stephenson MT, Piwnica-Worms H. C-TAK1 protein kinase phosphorylates human Cdc25C on serine 216 and promotes 14-3-3 protein binding. Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research. 1998; 9:197-208.
48. Duckworth BC, Weaver JS, Ruderman JV. G2 arrest in Xenopus oocytes depends on phosphorylation of cdc25 by protein kinase A. Proceedings of the National Academy of Sciences of the United States of America. 2002; 99:16794-16799.
49. Riester M, Taylor JM, Feifer A, Koppie T, Rosenberg JE, Downey RJ, Bochner BH, Michor F. Combination of a novel gene expression signature with a clinical nomogram improves the prediction of survival in high-risk bladder cancer. Clin Cancer Res. 2012; 18:1323-1333.
50. Hsu HP, Li CF, Lee SW, Wu WR, Chen TJ, Chang KY, Liang SS, Tsai CJ, Shiue YL. Overexpression of stathmin 1 confers an independent prognostic indicator in nasopharyngeal carcinoma. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine. 2014; 35:2619-2629.
51. Rigby CC, Franks LM. A human tissue culture cell line from a transitional cell tumour of the urinary bladder: growth, chromosone pattern and ultrastructure. British journal of cancer. 1970; 24:746-754.
52. Yeh MY, Yu DS, Chen SC, Lin MS, Chang SY, Ma CP, Han SH. Establishment and characterization of a human urinary bladder carcinoma cell line (TSGH-8301). Journal of surgical oncology. 1988; 37:177-184.
53. O'Toole C, Price ZH, Ohnuki Y, Unsgaard B. Ultrastructure, karyology and immunology of a cell line originated from a human transitional-cell carcinoma. British journal of cancer. 1978; 38:64-76.
54. Kuo KK, Chen YL, Chen LR, Li CF, Lan YH, Chang FR, Wu YC, Shiue YL. Involvement of phorbol-12-myristate-13-acetate-induced protein 1 in goniothalamin-induced TP53-dependent and -independent apoptosis in hepatocellular carcinoma-derived cells. Toxicology and applied pharmacology. 2011; 256:8-23.